Possis Aims To Reverse AngioJet Losses With JETSTENT Trial

Possis views its upcoming 500-patient JETSTENT trial as the final step in a three-part plan to overcome the damaging results of its 2004 AiMI study and recover lostAngioJet thrombectomy system sales